This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Sept. 4, 2013 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of MiMedx Group, Inc. ("MiMedx" or the "Company") (NasdaqCM: MDXG). The investigation focuses on whether the Company and its executives violated federal securities laws.
September 4, 2013, shares of MiMedx fell
$2.55 or 42.08% during intraday trading to trade at
$3.51 after theflyonthewall.com reported that the FDA indicated in a letter that the company is unlawfully manufacturing drugs at one of its plants. The letter stated MiMedx's Surgical Biologics unit violated the Public Health Service Act by unlawfully manufacturing drugs at one of its plants, and thereby marketed unapproved biologics products.
If you are aware of any facts relating to this investigation, or purchased shares of MiMedx, you can assist this investigation by contacting either
Peretz Bronstein or his Investor Relations Coordinator
Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email
firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or
Eitan Kimelman 212-697-6484
SOURCE Bronstein, Gewirtz & Grossman, LLC